Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Intellia Therapeutics ( (NTLA) ) has issued an update.
On April 28, 2026, Intellia Therapeutics entered into an underwriting agreement with Jefferies, Goldman Sachs, and Citigroup for a public offering of 16,744,187 common shares at $10.75 per share, plus a 30-day option for 2,511,628 additional shares that was fully exercised on April 29. The offering, which closed on April 30, 2026, was conducted under an existing shelf registration and generated estimated net proceeds of about $194.6 million for the company.
All shares in the transaction were sold by Intellia, which plans to use the capital to advance clinical development, prepare for the commercial launch of its lead programs, fund research on additional pipeline candidates, pursue potential acquisitions, and support working capital and general corporate purposes. The company expects that, together with existing cash, securities, and collaboration funding, the proceeds will finance operating and capital needs at least into 2028, strengthening its balance sheet ahead of a potential 2027 approval of lonvoguran ziclumeran for hereditary angioedema.
The most recent analyst rating on (NTLA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and cash burn) and limited valuation support (negative P/E, no dividend). Offsetting these are clinically and operationally positive updates—especially Phase 3 HAE results and regulatory progress—while technical signals are broadly neutral.
To see Spark’s full report on NTLA stock, click here.
More about Intellia Therapeutics
Intellia Therapeutics, Inc. is a biotechnology company focused on developing CRISPR-based gene-editing therapies. Its pipeline includes lead clinical programs such as lonvoguran ziclumeran for hereditary angioedema, with efforts directed toward advancing clinical development and preparing for future commercial launches in rare disease markets.
Average Trading Volume: 4,688,328
Technical Sentiment Signal: Sell
Current Market Cap: $1.47B
Learn more about NTLA stock on TipRanks’ Stock Analysis page.